# reload+after+2024-01-22 21:46:52.975636
address1§Paasheuvelweg 25
city§Amsterdam
zip§1105 BP
country§Netherlands
phone§31 20 240 6000
website§https://www.uniqure.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
fullTimeEmployees§501
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Matthew Craig Kapusta', 'age': 51, 'title': 'CEO & Executive Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 1157887, 'exercisedValue': 0, 'unexercisedValue': 4726089}, {'maxAge': 1, 'name': 'Mr. Christian  Klemt', 'age': 50, 'title': 'CFO, Principal Financial Officer & GM of Amsterdam Site', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 566360, 'exercisedValue': 0, 'unexercisedValue': 362614}, {'maxAge': 1, 'name': 'Mr. Pierre  Caloz', 'age': 51, 'title': 'Chief Operating Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 951104, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Hugo  Katus', 'title': 'Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard  Porter Ph.D.', 'title': 'Chief Business & Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeannette  Potts J.D., Ph.D.', 'age': 61, 'title': 'Chief Legal & Compliance Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Tamara  Tugal Ph.D., MBA', 'title': 'Business Development Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erin  Boyer', 'title': 'Chief People & Culture Office', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Maria E. Cantor', 'age': 55, 'title': 'Chief Corporate Affairs Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 491122, 'exercisedValue': 0, 'unexercisedValue': 1087760}, {'maxAge': 1, 'name': 'Dr. Amin  Abujoub Ph.D.', 'title': 'Chief Quality Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§5
shareHolderRightsRisk§1
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.077
priceToSalesTrailing12Months§2.8029153
currency§USD
dateShortInterest§1702598400
forwardEps§-3.98
exchange§NMS
quoteType§EQUITY
shortName§uniQure N.V.
longName§uniQure N.V.
firstTradeDateEpochUtc§1391610600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e051aa7b-edc2-3bc7-a8c8-c2e424dc5a80
gmtOffSetMilliseconds§-18000000
targetHighPrice§63.0
targetLowPrice§10.0
targetMeanPrice§29.62
targetMedianPrice§28.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§13
quickRatio§9.628
grossMargins§-0.98397005
ebitdaMargins§-1.5180401
trailingPegRatio§None
